The IDH-mutant type, observed in the KT1 case, was the only IDH mutant in ICC which seemed relatively rare in ICC, which did not alter the BCAA degradation pathway, and which produced specific metabolites that contributed to tumorigenesis [33]. Here, IDH2 is linked to intrahepatic cholangiocarcinoma.